Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | ACHE | P22303 | 3/20 | 0.70 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8062100 | 0.91 | MEN1 (0.71) | MEN1KMT2AALDH1A1L3MBTL1ACHE | |
| SCHEMBL6904467 | 0.89 | ABCB1 (0.70) | MEN1KMT2AALDH1A1L3MBTL1ACHE | |
| SCHEMBL24514601 | 0.88 | ABCB1 (0.73) | MEN1KMT2AALDH1A1L3MBTL1ACHE | |
| SCHEMBL4649969 | 0.88 | ABCB1 (0.73) | MEN1KMT2AALDH1A1L3MBTL1ACHE | |
| SCHEMBL7156543 | 0.88 | ABCB1 (0.69) | MEN1KMT2AALDH1A1L3MBTL1ACHE | |
| SCHEMBL29979584 | 0.88 | L3MBTL1 (0.79) | MEN1KMT2AALDH1A1L3MBTL1ACHE | |
| SCHEMBL21515195 | 0.88 | L3MBTL1 (0.69) | MEN1KMT2AL3MBTL1ACHECYP1A1 | |
| SCHEMBL21490234 | 0.86 | CREB1 (0.70) | MEN1KMT2AALDH1A1L3MBTL1ACHE | |
| SCHEMBL21206267 | 0.86 | ABCB1 (0.73) | MEN1KMT2AALDH1A1ACHECYP1A1 | |
| SCHEMBL30376265 | 0.86 | ABCB1 (0.73) | MEN1KMT2AALDH1A1ACHECYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138165-B2 | Chromones and chromone derivatives and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-1556031-A4 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | JENKEN BIOSCIENCES INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20060142211-A1 | Chromones and chromone derivatives and uses thereof | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2006-06-29 | — | — | US | disclosed |
| EP-1556031-A2 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | Jenken Bioscience, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037193-A2 | CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF | JENKEN BIOSCIENCES, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142211-A1 | Chromones and chromone derivatives and uses thereof | PROC, HMGB1, PYCARD | MEN1 1195/4885KMT2A 4070/4885ALDH1A1 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.